The news: Novo rolled out several updates to its direct-to-consumer (D2C) patient support platform, NovoCare. Most updates target Wegovy patients, though some also apply to Ozempic users.
Three key updates to NovoCare include:
Why it matters: Novo is likely bolstering NovoCare to attract patients choosing between Wegovy and Eli Lilly’s rival Zepbound, and to keep existing Wegovy users on treatment.
GLP-1 discontinuation remains a major challenge for drugmakers. Some 65% of users without type 2 diabetes stop treatment within a year, per a study published last year in JAMA Network Open. Most of NovoCare’s new offerings don’t directly address common reasons for stopping treatment, including cost, insurance changes, side effects, and reaching weight loss goals. But rewards redeemable with brands that meet GLP-1 users’ support needs, along with treatment tracking and app-based guidance, could help keep patients engaged and improve retention.
NovoCare’s app should also simplify access to health recommendations that GLP-1 users otherwise patch together across multiple sources. Just 23% of current GLP-1 users feel well supported by wellness platforms, including apps, subscriptions, and connected services, in helping them manage fitness, nutrition, and overall well-being, per a May PwC survey.
Implications for GLP-1 marketers: Even as Lilly and Novo expand their D2C support platforms, most people turn elsewhere for medication and related information. Some 17% of consumers have used a pharma D2C website for telehealth or prescription drug access, per our January 2026 US Digital Health Survey. Awareness among the rest is thin: Only 5% of nonusers are very or extremely familiar with these offerings, while 54% are not at all familiar. Many prospective GLP-1 users are likely unaware of support programs like NovoCare and LillyDirect.
Consumers who have used pharma D2C websites most commonly discover them through the sites themselves, social media ads, and search ads, per our survey. GLP-1 marketers should use these channels to promote new patient support services, wellness perks, and the benefits of signing up. TV and CTV are also key channels for reaching seniors newly eligible for weight loss medications through Medicare Bridge, many of whom may need guidance navigating treatment and support options as first-time users.
This content is part of EMARKETER’s subscription Briefings, where we pair daily updates with data and analysis from forecasts and research reports. Our Briefings prepare you to start your day informed, to provide critical insights in an important meeting, and to understand the context of what’s happening in your industry. Not a subscriber? Click here to get a demo of our full platform and coverage.
You've read 0 of 2 free articles this month.
685 Third Avenue21st FloorNew York, NY 100171-800-405-0844
1-800-405-0844[email protected]